STOCK TITAN

IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
IDEAYA Biosciences, Inc. (IDYA) will be participating in the Stifel Virtual Targeted Oncology Forum on April 16th, 2024. The event will feature a fireside chat with CEO Yujiro S. Hata. A live audio webcast will be available on the company's website, with replays accessible for 30 days.
Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., April 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.

Stifel Virtual Targeted Oncology Forum
Tuesday, April 16th, 2024 at 12:00 PM ET

  • Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Benjamin Burnett, Ph.D., Managing Director, Equity Analyst

A live audio webcast of conference event, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host.  A replay of available webcasts will be accessible for 30 days following the live event.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Annual Report on Form 10-K filed on February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact

IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-april-2024-investor-relations-event-302101640.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

When is IDEAYA Biosciences participating in the Stifel Virtual Targeted Oncology Forum?

IDEAYA Biosciences is participating in the Stifel Virtual Targeted Oncology Forum on April 16th, 2024.

Who will be hosting the fireside chat with CEO Yujiro S. Hata?

The fireside chat with CEO Yujiro S. Hata will be hosted by Benjamin Burnett, Ph.D., Managing Director, Equity Analyst.

Where can the live audio webcast of the conference event be accessed?

The live audio webcast of the conference event can be accessed on the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host.

How long will the replays of the webcasts be accessible?

Replays of the webcasts will be accessible for 30 days following the live event.

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

IDYA Rankings

IDYA Latest News

IDYA Stock Data

3.10B
73.78M
0.98%
102.9%
12.62%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SOUTH SAN FRANCISCO

About IDYA

ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california.